Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hasselblad

Showing results (231-240 of 250) with videos related to

Pageof 25
Sort By:
Circulation. Heart Failure|October 5, 2014
Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HFPriyesh A Patel, Gretchen Heizer, Christopher M O'Connor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 2, 2010
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantationDavid A Rizzieri, Robert Storms, Dong-Feng Chen, et al.
Medical Care|August 1, 2020
Impact of a Follow-up Telephone Call Program on 30-Day Readmissions (FUTR-30): A Pragmatic Randomized Controlled Real-world Effectiveness TrialMaame Yaa A B Yiadom, Henry J Domenico, Daniel W Byrne, et al.
Circulation|May 22, 2002
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluationChristopher K Dyke, Richard C Becker, Neal S Kleiman, et al.
JAMA|July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overviewJohn L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
American Heart Journal|February 3, 2009
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)Adrian F Hernandez, Christopher M O'Connor, Randall C Starling, et al.
Gene Therapy|December 22, 2025
Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected casesPhilipp Berg, Charlotte Bakker, Moritz Sander, et al.
American Heart Journal|August 25, 2015
Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome modelsPrateeti Khazanie, Gretchen M Heizer, Vic Hasselblad, et al.
Circulation. Cardiovascular Quality and Outcomes|June 30, 2011
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trialsPierluigi Tricoci, L Kristin Newby, Vic Hasselblad, et al.
International Journal of Cardiology|February 12, 2013
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudySean van Diepen, L Kristin Newby, Renato D Lopes, et al.
Pageof 25

Showing results (231-240 of 250) with videos related to

Sort By:
Pageof 25
Circulation. Heart Failure|October 5, 2014
Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HFPriyesh A Patel, Gretchen Heizer, Christopher M O'Connor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 2, 2010
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantationDavid A Rizzieri, Robert Storms, Dong-Feng Chen, et al.
Medical Care|August 1, 2020
Impact of a Follow-up Telephone Call Program on 30-Day Readmissions (FUTR-30): A Pragmatic Randomized Controlled Real-world Effectiveness TrialMaame Yaa A B Yiadom, Henry J Domenico, Daniel W Byrne, et al.
Circulation|May 22, 2002
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluationChristopher K Dyke, Richard C Becker, Neal S Kleiman, et al.
JAMA|July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overviewJohn L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
American Heart Journal|February 3, 2009
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)Adrian F Hernandez, Christopher M O'Connor, Randall C Starling, et al.
Gene Therapy|December 22, 2025
Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected casesPhilipp Berg, Charlotte Bakker, Moritz Sander, et al.
American Heart Journal|August 25, 2015
Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome modelsPrateeti Khazanie, Gretchen M Heizer, Vic Hasselblad, et al.
Circulation. Cardiovascular Quality and Outcomes|June 30, 2011
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trialsPierluigi Tricoci, L Kristin Newby, Vic Hasselblad, et al.
International Journal of Cardiology|February 12, 2013
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudySean van Diepen, L Kristin Newby, Renato D Lopes, et al.
Pageof 25